1
|
Ortiz Jordan LM, Vega VF, Shumate J, Peles A, Zeiger J, Scampavia L, Spicer TP. Protocol for high throughput 3D drug screening of patient derived melanoma and renal cell carcinoma. SLAS Discov 2024; 29:100141. [PMID: 38218316 DOI: 10.1016/j.slasd.2024.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 12/29/2023] [Accepted: 01/10/2024] [Indexed: 01/15/2024]
Abstract
High Throughput Screening (HTS) with 3D cell models is possible thanks to the recent progress and development in 3D cell culture technologies. Results from multiple studies have demonstrated different drug responses between 2D and 3D cell culture. It is now widely accepted that 3D cell models more accurately represent the physiologic conditions of tumors over 2D cell models. However, there is still a need for more accurate tests that are scalable and better imitate the complex conditions in living tissues. Here, we describe ultrahigh throughput 3D methods of drug response profiling in patient derived primary tumors including melanoma as well as renal cell carcinoma that were tested against the NCI oncologic set of FDA approved drugs. We also tested their autologous patient derived cancer associated fibroblasts, varied the in-vitro conditions using matrix vs matrix free methods and completed this in both 3D vs 2D rendered cancer cells. The result indicates a heterologous response to the drugs based on their genetic background, but not on their maintenance condition. Here, we present the methods and supporting results of the HTS efforts using these 3D of organoids derived from patients. This demonstrated the possibility of using patient derived 3D cells for HTS and expands on our screening capabilities for testing other types of cancer using clinically approved anti-cancer agents to find drugs for potential off label use.
Collapse
Affiliation(s)
- Luis M Ortiz Jordan
- High-Throughput Molecular Screening Center, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 130 Scripps Way #1A1, Jupiter, FL 33458, USA
| | - Virneliz Fernández Vega
- High-Throughput Molecular Screening Center, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 130 Scripps Way #1A1, Jupiter, FL 33458, USA
| | - Justin Shumate
- High-Throughput Molecular Screening Center, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 130 Scripps Way #1A1, Jupiter, FL 33458, USA
| | - Adam Peles
- High-Throughput Molecular Screening Center, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 130 Scripps Way #1A1, Jupiter, FL 33458, USA
| | - Jordan Zeiger
- High-Throughput Molecular Screening Center, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 130 Scripps Way #1A1, Jupiter, FL 33458, USA
| | - Louis Scampavia
- High-Throughput Molecular Screening Center, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 130 Scripps Way #1A1, Jupiter, FL 33458, USA
| | - Timothy P Spicer
- High-Throughput Molecular Screening Center, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 130 Scripps Way #1A1, Jupiter, FL 33458, USA.
| |
Collapse
|